Benjamin Daquioag.
Phone number 713-526-9821 ext217

TMC435HEPC3001

A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNα and ribavirin therapy.

Copyright © 2017. Cure C Consortium